Pfizer to acquire small molecule anti-infective business from AstraZeneca
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States.
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer's disease
- Details
- Category: AstraZeneca
AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer's disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial.
Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA
- Details
- Category: Bayer
Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therapeutics agreed to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease.
Esketamine receives Breakthrough Therapy Designation from FDA for major depressive disorder with imminent risk for suicide
- Details
- Category: Johnson & Johnson
Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for esketamine, an investigational antidepressant medication, for the indication of major depressive disorder with imminent risk for suicide.
Amgen and Advaxis enter global cancer immunotherapies collaboration
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Advaxis, Inc. (NASDAQ:ADXS) announced a global agreement for the development and commercialization of Advaxis' ADXS-NEO, a novel, preclinical investigational cancer immunotherapy treatment that is designed to activate a patient's immune system to respond against the unique mutations, or neoepitopes, contained in and identified from each individual patient's tumor.
Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
- Details
- Category: Novartis
Today Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbourne, Australia on Aug 22, 2016. The Novartis Prizes for Immunology are awarded every three years for breakthrough contributions to the fields of basic and clinical immunology.
Pfizer announces publication of new analysis showing long-term therapy with VYNDAQEL (tafamidis) slowed progression of rare neurodegenerative disease
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5.5 years, showed
More Pharma News ...
- Vonvendi, the first and only recombinant treatment for adults affected by von Willebrand disease, launches in the USA
- GSK and Verily to establish Galvani Bioelectronics - a new company dedicated to the development of bioelectronic medicines
- Boehringer Ingelheim: Growth in all core businesses
- Novartis CDK4/6 inhibitor LEE011 (ribociclib) receives FDA Breakthrough Therapy designation as first-line treatment for HR+/HER2- advanced breast cancer
- Pfizer aims to become industry leader in gene therapy with acquisition of Bamboo Therapeutics, Inc.
- Bristol-Myers Squibb reports second quarter financial results
- Merck receives Breakthrough Therapy Designation from FDA and PRIME status from EMA for investigational Ebola Zaire vaccine (V920)